BG Medicine Posts 62 Percent Jump in Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $1 million, up 62 percent from $622,000 in the second quarter of 2012.

The revenue increase was driven by $972,000 in revenues from sales of the company's BGM Galectin-3 test, a 72 percent jump from the $566,000 it posted in Q2 2012. The remaining $34,000 in revenues came from BG's services business, down 39 percent from $56,000 a year ago.

The company's revenues fell short of the average Wall Street estimate of $1.27 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.